What is the Return on Assets (ROA) of Haemonetics this year?
The Return on Assets (ROA) of Haemonetics is 0.05 undefined this year.
Haemonetics ROA 2024
Haemonetics ROA
0.05
Ticker
HAE
ISIN
US4050241003
WKN
881782
In 2024, Haemonetics's return on assets (ROA) was 0.05, a 129.43% increase from the 0.02 ROA in the previous year.
Haemonetics Aktienanalyse
What does Haemonetics do?
Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Haemonetics's Return on Assets (ROA)
Haemonetics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Haemonetics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Haemonetics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Haemonetics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Haemonetics stock
What was the ROA of Haemonetics compared to the previous year?
The ROA of Haemonetics has increased by 129.43% compared to the previous year.
What consequences do high ROA have for investors of Haemonetics?
A high ROA is advantageous for investors of Haemonetics, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Haemonetics?
A low ROA can be unfavorable for investors of Haemonetics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Haemonetics affect the company?
An increase in ROA of Haemonetics can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Haemonetics impact the company?
A reduction in the ROA of Haemonetics can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Haemonetics?
Some factors that can influence the ROA of Haemonetics include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Haemonetics important for investors?
The ROA of Haemonetics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Haemonetics take to improve ROA?
To improve ROA, Haemonetics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Haemonetics pay?
Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.
What is the dividend yield of Haemonetics?
The current dividend yield of Haemonetics is .
When does Haemonetics pay dividends?
Haemonetics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Haemonetics?
Haemonetics paid dividends every year for the past 0 years.
What is the dividend of Haemonetics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Haemonetics located?
Haemonetics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemonetics from 7/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2024.
When did Haemonetics pay the last dividend?
The last dividend was paid out on 7/13/2024.
What was the dividend of Haemonetics in the year 2023?
In the year 2023, Haemonetics distributed 0 USD as dividends.
In which currency does Haemonetics pay out the dividend?
The dividends of Haemonetics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemonetics
Our stock analysis for Haemonetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemonetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
